(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/199234 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 25/14* (2006.01)
A61K 31/4375 (2006.01) *A61P 25/28* (2006.01)
A61P 25/08 (2006.01)

(21) International Application Number:
PCT/US2025/020561

(22) International Filing Date:
19 March 2025 (19.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/567,664 20 March 2024 (20.03.2024) US
63/761,354 21 February 2025 (21.02.2025) US

(71) Applicant: **NEUROCRINE BIOSCIENCES, INC.** [US/US]; 6027 Edgewood Bend Court, San Diego, CA 92130 (US).

(72) Inventors: **BOON, Byron, A.**; c/o Neurocrine Biosciences, Inc., 6027 Edgewood Bend Court, San Diego, CA 92130 (US). **GU, Jieyu**; c/o Neurocrine Biosciences, Inc., 6027 Edgewood Bend Court, San Diego, CA 92130 (US). **XUE, Yibin**; c/o Neurocrine Biosciences, Inc., 6027 Edgewood Bend Court, San Diego, CA 92130 (US). **PAGANO, Nicholas**; c/o Neurocrine Biosciences, Inc., 6027 Edgewood Bend Court, San Diego, CA 92130 (US).

(74) Agent: **SEARS, Justin, Edward** et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, MN 55440 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2025/199234 A1

(54) Title: VMAT2 INHIBITORS AND METHODS OF USE



(Ia)

(57) Abstract: This disclosure relates to, *inter alia*, certain compounds, compositions, and pharmaceutical compositions thereof, that modulate the activity of the transporter protein vesicular monoamine transporter- 2 (VMAT2) and are directed to methods useful in the treatment of transporter protein vesicular monoamine transporter-2 mediated disorders, such as, neurological or psychiatric disease or disorders, including but not limited to, hyperkinetic movement disorders (e.g., tardive dyskinesia, Tourette's syndrome, Huntington's disease, tics, ataxia, chorea (such as, chorea associated with Huntington's disease), dystonia, hemifacial spasm, myoclonus, restless leg syndrome, and tremors). The disclosure further relates to synthetic methods and intermediates useful in the preparation of compounds.